Feed SCYX
SC

SCYNEXIS, Inc. SCYX · NASDAQ

$3.66 -0.27% (-$0.01)

Market cap
$23.0M
Enterprise value
$14.5M
P/E
-
Forward P/E
-
PEG
-
P/S
1.2x
P/FCF
-
EV/EBITDA
-
ROIC
-32.4%
Gross margin
100.0%
Net margin
-53.3%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.06
Free float
96.5%

About the company

SCYNEXIS, Inc. (SCYX) is a biotechnology company specializing in research, development, and commercialization of novel drugs for the treatment of infectious diseases. The company focuses on the discovery and development of innovative drugs targeting various types of infectious diseases, including fungal infections and resistant bacteria. SCYNEXIS aims to develop drugs that are effective and safe for patients with infectious diseases and can bring improvements in the treatment of these conditions. The company also conducts clinical trials and collaborates with medical institutions and pharmaceutical companies to further develop and commercialize its drugs. SCYNEXIS, Inc. (SCYX) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company with a focus on developing new drugs for the treatment of infectious diseases.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

CEO

David Angulo

Employees

18

Headquarters

Jersey City

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.